Tempus AI reported a second-quarter revenue boost driven by strong oncology testing demand, citing continued momentum from FDA approvals. The company raised full-year 2026 revenue guidance to $1.6 billion–$1.61 billion and tied growth to uptake of its xT CDx sequencing platform and expansion of liquid biopsy testing. Tempus also reiterated that its minimal residual disease business is set to benefit from its planned acquisition of Personalis, expected to accelerate commercial adoption of MRD testing. CEO Eric Lefkofsky pointed to a potential $400 million revenue uplift in 2028 tied to xT CDx and anticipated xF approvals. The update reflects how regulated companion diagnostics and MRD frameworks are increasingly becoming revenue growth engines, with guidance increasingly linked to regulatory and integration milestones rather than only clinical study progression.